Vertebral Artery Stenosis Clinical Trial
— VOTEROfficial title:
Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)
Verified date | January 2024 |
Source | St. Louis University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
A prospective registry of patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).
Status | Active, not recruiting |
Enrollment | 100 |
Est. completion date | December 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: 1. Patients between 18 and 90 years of age 2. Patient has experienced a posterior circulation ischemic event 3. Patient has angiographically confirmed bilateral vertebral artery origin disease (Hypoplasia, occlusion, or stenosis). 4. Patient has >50% stenosis on the side being targeted for therapy Exclusion Criteria: 1. Pregnant women 2. Contrast Indication to the use of anti-platelet drugs 3. There is tandem vertebral or basilar artery stenosis 4. The serum creatinin is >2.5 5. Baseline modified Rankin score is >3 6. < 5 years life expectancy |
Country | Name | City | State |
---|---|---|---|
United States | SSM DePaul Hospital | Bridgeton | Missouri |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | Texas Tech University Health Science Center of El Paso | El Paso | Texas |
United States | University of Iowa | Iowa City | Iowa |
United States | Baptist Medical Center Jacksonville | Jacksonville | Florida |
United States | Semmes Murphey Clinic | Memphis | Tennessee |
United States | Saint Louis University | Saint Louis | Missouri |
United States | University of Southern Florida | Tampa | Florida |
United States | Mercy Health Neuroscience Institute | Toledo | Ohio |
United States | Northwestern Medicine Regional Medical Group | Winfield | Illinois |
Lead Sponsor | Collaborator |
---|---|
St. Louis University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of recurrent stroke or death | Recurrent stroke of any type or death from any cause | 1 Year post-treatment | |
Secondary | Incidence of Restenosis | Restenosis in VAOS patients treated with drug-eluting stents. | 1 Year post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06186024 -
A PROSPECTIVE, MULTICENTER, SINGLE-ARM TRIAL FOR THE NEW SIZES OF BRIDGE STENTS FOR VERTEBRAL ARTERY STENOSIS: Bridge-MAX
|
N/A | |
Recruiting |
NCT03504657 -
Drug-coated Balloon Angioplasty for Patients With Symptomatic Vertebral Artery Stenosis
|
Phase 2 | |
Completed |
NCT03201432 -
Drug Eluting Stents Versus Bare Metal Stents for Treatment of Symptomatic Extracranial Vertebral Artery Stenosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05644314 -
Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis
|
N/A | |
Completed |
NCT03859674 -
Firehorus Rapamycin Target Eluting Vertebral Artery Stent System in Clinical Application
|
N/A | |
Recruiting |
NCT06301776 -
A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge
|
N/A | |
Recruiting |
NCT05885932 -
Drug-eluting Stenting Versus Medical Treatment for Extracranial Vertebral Artery Stenosis
|
N/A | |
Recruiting |
NCT00172458 -
Clinical Results and Restenosis Analysis of Symptomatic Ostial Vertebral Artery Stenosis Treated With Tubular Coronary Stents
|
N/A |